Akeso Biopharma, Inc.

Shenzhen China Star Optoelectronics Semiconductor Display Technology Co., Ltd.

Ad Pharmaceutical Co., Inc.

Zte Corporation

Guangdong Brunp Recycling Technology Co., Ltd

Hunan Brunp Recycling Technology Co. Ltd.

Dongguan University of Technology

Focaltech Systems, Ltd.

Akeso Pharmaceuticals, Inc.

Zeda Biopharmaceuticals, Inc.

Cttq-akeso (shanghai) Biomed. Tech. Co., Ltd.

Huawei Technologies Co., Limited

Guangdong Broadradio Communication Technology Co., Ltd.

Cttq-akeso Biomed. Tech. Co., Ltd.

Peng Zhang

Dan Liu

Wei Hu

Yu Xia

Baiyong Li

Zhongmin Maxwell Wang

Xinghua Pang

Yuanyuan Xu

Dongsheng Dai

Jinan Jiao

Wuxian Ren

Changdong Li

Lianghua Mo

Dingshan Ruan

Tao Wang

Xinxi Jiang

Zhenhua Xu

Yan Ding

Biqun Wu

Feifei Zhang

Changlong Sun

Shijian Tang

Yuntao Liu

Longbo Guo

Zhiwen Liu

Jianhua Mai

Weijie Ma

Yan-Jie Wang

Shao Zhang

Benbo Luo

Zehai Wu

A display device is provided. A display panel includes a display device. The display device is provided with a gate driving area. The gate driving area is provided with a first transistor device. The first transistor device includes a first signal wire and a second signal wire. The first signal wire is electrically connected to a gate layer. The second signal wire is electrically connected to a first metal layer. Therefore, a double-gate structure, which can provide a large-current gate signal by only the second signal wire, is formed. Or, the double-gate structure can provide a large-current gate signal by both the first signal wire and the second signal wire. As a result, mobility of an active layer is improved.

Display device

The present invention belongs to the fields of tumor therapy and molecular immunology, and provides an anti-CTLA4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition thereof and use thereof. The monoclonal antibody of the present invention can block the binding of CLTA4 to B7, relieve the immunosuppression on the body by CTLA4, and activate T lymphocytes.

Anti-CTLA4 monoclonal antibody or its antigen binding fragments, pharmaceutical compositions and uses

The present invention belongs to the field of immunology, and relates to an anti-IL-1β antibody and pharmaceutical composition thereof and use of the same. Specifically, the present invention relates to an anti-IL-1β antibody or an antigen-binding fragment thereof, wherein a heavy chain variable region of the antibody comprises HCDR1-HCDR3 with amino acid sequences set forth in SEQ ID NO: 17-SEQ ID NO: 19, respectively; and a light chain variable region of the antibody comprises LCDR1-LCDR3 set forth in SEQ ID NO: 20-SEQ ID NO: 22, respectively. The antibody disclosed herein can effectively bind to human IL-1B, block the binding of IL-1B to a receptor IL-1R1 thereof, and inhibit the activation of downstream signaling pathways of IL-1B; having the potential of being used for preparing a medicament for preventing and treating autoimmune diseases, cryopyrin-associated periodic syndromes in children and adults, systemic juvenile idiopathic arthritis, gouty arthritis, cardiovascular diseases or tumors.

Anti-IL-1β antibody and pharmaceutical composition thereof and use of same

The present application relates to the fields of tumor treatment and molecular immunology, and specifically, to an anti-VEGFA/PD-1 bifunctional antibody, a pharmaceutical composition thereof and use thereof. Specifically, the anti-VEGFA/PD-1 bifunctional antibody comprises an antibody or antigen binding fragment thereof targeting VEGFA and an antibody or antigen binding fragment thereof targeting PD-1. The bifunctional antibody can specifically bind to VEGFA and PD-1, specifically relieve immunosuppression of VEGFA and PD-1 in an organism, and inhibit tumor-induced angiogenesis.

Anti-PD-1/VEGFA bifunctional antibody, pharmaceutical composition thereof

A method for enriching lithium from a lithium clay includes the following steps (1) the raw ore were crushed to produce fine particles, (2) performing rougher on the fine particles by adding ferric sulfate or ferric nitrate, sodium oleate, and cocoamine to obtain rough concentrate and rough tailing, (3) finely separating the rough concentrate to obtain the first part of concentrate, (4) re-grinding the rough tailing by ball mill, (5) performing rougher on the reground tailing to obtain reground rough concentrate and re-ground rough tailing, (6) performing cleaner on the reground rough concentrate to obtain the second part of concentrate, and (7) performing scavenger on the reground rough tailing to obtain the cleaned tailing.

Method for enriching lithium from lithium clay

An anti-PDl (programmed cell death 1) monoclonal antibody or an antigen-binding fragment thereof, a pharmaceutical composition thereof and use thereof. The heavy chain variable region of the monoclonal antibody comprises CDRs (complementary determining region) of amino acid sequences as shown in SEQ ID NO:9-11; and/or the light chain variable region of the monoclonal antibody comprises CDRs of amino acid sequences as shown in SEQ ID NO: 12-14. The monoclonal antibody can bind to PDl specifically, relieve immunosuppression of PDl on an organism specifically and activate T lymphocytes.

Anti-PD1 monoclonal antibody, pharmaceutical composition thereof and use thereof

Pet gate

Provided are antibodies or antigen binding fragments thereof, which can bind to human IL-1β, block the binding of IL-1β to receptors thereof and thereby down regulate the activity of IL-1β, and can be used to prepare drugs for the treatment of immune diseases mediated by IL-1β overexpression such as arthritis, osteoporosis, and tumor necrosis factor receptor-associated periodic syndrome.

Antibody binding to human IL-1β, preparation method therefor and use thereof

Provided are a system and method for implementing an incremental data comparison. The system includes: a synchronization T environment, a simulation F environment, a simulation tool, a memory database, a comparison tool and a result database. The T environment includes a synchronization environment core application, a traditional commercial database, an incremental synchronization tool and a synchronization environment distributed database. The F environment includes a simulation environment core application and a simulation environment distributed database. The simulation tool is configured to play back a T environment service and an F environment service. The memory database is configured to store a mapping relationship between message values of the T and F environment. The comparison tool is configured to compare data in the T and F environment according to the mapping relationship between the message values. The result database is configured to store comparison result data generated by the comparison tool.

System and method for implementing incremental data comparison

An array substrate, a manufacturing method thereof, and a display panel are provided. The array substrate includes an active layer, a metal contact layer, a gate insulating layer, a gate layer, a source/drain layer, and a pixel electrode, which are sequentially disposed on a substrate. An insulating area of the metal contact layer corresponds to a channel area of the active layer, and a conductive area of the metal contact layer is disposed at two sides of the insulating area. A source and a drain of the source/drain layer are individually connected to the conductive area. Therefore, a problem of relatively high electrical resistance of a conductorized IGZO area in conventional TFT devices can be solved.

Array substrate, manufacturing method thereof, and display panel

The present invention discloses a monoclonal antibody against nerve growth factor, and an encoding gene and use thereof. The monoclonal antibody against nerve growth factor of the present invention comprises heavy chains comprising a heavy chain constant region and a heavy chain variable region, and light chains comprising a light chain constant region and a light chain variable region. The heavy chain variable region comprises three complementarity determining regions HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises three complementarity determining regions LCDR1, LCDR2 and LCDR3. The monoclonal antibody against nerve growth factor of the present invention can specifically bind to nerve growth factor, and can be used to detect the presence and/or level of nerve growth factor, as well as to prepare a drug for inhibiting the nerve growth factor-dependent proliferation of TF-1 cells, and to prepare a drug for treating or preventing at least one of neuropathic pain, chronic pain, and inflammatory pain, thus having good application prospects and marketing value.

Monoclonal antibody against nerve growth factor, and encoding gene and use thereof

An anti-CTLA4 (cytotoxic T lymphocyte associated antigen 4) and anti-PD-1 (programmed cell death 1) bifunctional antibody. a pharmaceutical composition thereof and use thereof. Particularly, the anti-CLTA4 and anti-PD-1 bifunctional antibody comprises a first protein functional domain that targets PD-1 and a second protein functional domain that targets CTLA-4. The bifunctional antibody can bind to CTLA-4 and PD-1 specifically, relieve immunosuppression of CTLA4 and PD-1 on an organism specifically, activate T lymphocytes, and thus has good application prospects.

Anti-CTLA4 and anti-PD-1 bifunctional antibody, pharmaceutical composition thereof and use thereof

The present disclosure discloses a method for preparing an anode material for lithium ion battery of a SiC nanoparticle encapsulated by nitrogen-doped graphene. The method includes: in an ammonia atmosphere, heating a SiC nanoparticle for a predetermined time, and cooling to obtain the SiC nanoparticle encapsulated by nitrogen-doped graphene.

Method for preparing anode material for lithium ion battery of SiC nanoparticle encapsulated by nitrogen-doped graphene

The present invention belongs to the fields of tumor therapy and molecular immunology. The present invention relates to an anti-CTLA4 antibody, pharmaceutical composition and use thereof. The anti-CTLA4 antibody of the present invention can specifically bind CTLA4, and can very effectively block the binding of CLTA4 to B7.

Anti-CTLA4 antibodies

The present invention belongs to the field of immunology and molecular biology, which relates to an anti-PCSK9 antibody, the pharmaceutical composition and method of use thereof. In particular, the present invention relates to the monoclonal antibody, which can bind PCSK9 specifically, block association of PCSK9 with LDLR, upregulate the amount of LDLR on cell surface, heighten the metabolism of LDL cholesterol and/or triglycerides, and prevent/treat cardiovascular diseases caused by hypercholesterolemia.

Nucleic acid encoding PCSK9 antibody

Growing community of inventors

Guangdong, China

Peng Zhang